Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Risk of mortality and cancer incidence in Barrett's esophagus
Cancer Epidemiology Biomarkers and Prevention, Volume 16, No. 10, Year 2007
Notification
URL copied to clipboard!
Description
Background: There are very few prospective follow-up studies of Barrett esophagus (BE) cohorts assessing the risk of extraesophageal cancer incidence or mortality. Such studies are necessary in order to understand the overall risks of cancer and death experienced by patients with BE. Methods: A cohort of 502 patients with BE were identified at Leeds General Infirmary, England. Mortality and cancer incidence information were provided by the Office for National Statistics. Standardized mortality ratios (SMR) and standardized incidence ratios (SIR) were calculated using indirect standardization. Results: All-cause mortality was found to be elevated in patients with BE [SMR, 1.21; 95% confidence interval (95% CI), 1.06, 1.37] and remained so after esophageal cancers were excluded (SMR, 1.16; 95% CI, 1.01-1.32). Increased mortality risks were also found for malignant neoplasms of the esophagus (SMR, 7.26; 95% CI, 3.87-12.42) and diseases of the digestive system (SMR, 2.03; 95% CI, 1.11-3.40). The remaining disease categories produced no altered risk estimates. Circulatory disease mortality was borderline statistically significant (SMR, 1.24; 95% CI, 1.00-1.52; P = 0.053) for those with a specialized intestinal metaplasia diagnosis of BE. In the cancer incidence analyses, esophageal malignancies (SIR, 8.66; 95% CI, 4.73-14.53) and esophageal adenocarcinomas (SIR, 14.29; 95% CI, 7.13-22.56) were found to be increased in BE. All remaining analyses provided unaltered risks, including that of colorectal cancer. Conclusions: This study has shown evidence of an increased risk of esophageal cancer incidence and mortality in BE. It has also shown that those who have a histologic BE diagnosis may also have an increased risk of circulatory disease mortality. Copyright © 2007 American Association for Cancer Research.
Authors & Co-Authors
Cook, Michael Blaise
United Kingdom, Leeds
University of Leeds, School of Medicine
Wild, Christopher Paul
United Kingdom, Leeds
University of Leeds, School of Medicine
Everett, Simon M.
United Kingdom, Leeds
University of Leeds, School of Medicine
Hardie, Laura J.
United Kingdom, Leeds
University of Leeds, School of Medicine
Bani-Hani, Kamal Eddin
Jordan, Irbid
Jordan University of Science and Technology
Martin, Iain G.
New Zealand, Auckland
School of Medicine
Forman, David F.
United Kingdom, Leeds
University of Leeds, School of Medicine
United Kingdom, Leeds
University of Leeds
Statistics
Citations: 72
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1158/1055-9965.EPI-07-0432
ISSN:
10559965
Research Areas
Cancer
Study Design
Cohort Study